Inogen, Inc (NASDAQ:INGN) – Stock analysts at Leerink Swann decreased their Q4 2017 earnings estimates for shares of Inogen in a research report issued to clients and investors on Tuesday. Leerink Swann analyst D. Antalffy now anticipates that the medical technology company will earn $0.18 per share for the quarter, down from their previous estimate of $0.21. Leerink Swann currently has a “Outperform” rating and a $120.00 price target on the stock. Leerink Swann also issued estimates for Inogen’s Q2 2018 earnings at $0.44 EPS, Q3 2018 earnings at $0.42 EPS, Q4 2018 earnings at $0.30 EPS, FY2020 earnings at $1.98 EPS and FY2021 earnings at $2.39 EPS.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a report on Thursday. Needham & Company LLC boosted their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 target price on shares of Inogen in a research note on Tuesday, September 12th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $103.14.

ILLEGAL ACTIVITY WARNING: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.watchlistnews.com/q4-2017-earnings-forecast-for-inogen-inc-ingn-issued-by-leerink-swann/1695701.html.

Shares of Inogen (INGN) opened at $114.19 on Thursday. Inogen has a fifty-two week low of $59.84 and a fifty-two week high of $124.90. The company has a market cap of $2,498.60, a P/E ratio of 97.33, a P/E/G ratio of 5.03 and a beta of 0.99.

Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The company had revenue of $69.00 million during the quarter, compared to the consensus estimate of $63.55 million. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The company’s revenue was up 26.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.25 EPS.

Several institutional investors and hedge funds have recently modified their holdings of the company. Schroder Investment Management Group purchased a new position in shares of Inogen during the 2nd quarter valued at about $132,000. Ameritas Investment Partners Inc. grew its position in shares of Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after buying an additional 86 shares during the last quarter. Sei Investments Co. grew its position in shares of Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock worth $153,000 after buying an additional 443 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Inogen by 17.8% in the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock worth $194,000 after buying an additional 307 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Inogen in the 1st quarter worth approximately $203,000.

In other news, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the transaction, the director now owns 7,808 shares in the company, valued at approximately $715,759.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Matt Scribner sold 2,500 shares of the stock in a transaction on Friday, August 18th. The stock was sold at an average price of $92.45, for a total value of $231,125.00. Following the transaction, the executive vice president now owns 6,964 shares of the company’s stock, valued at approximately $643,821.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 67,000 shares of company stock valued at $6,424,010. Insiders own 5.31% of the company’s stock.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.